Such damage could be precipitated by the following scenarios: i) Strategies aimed at reducing FMRP activity in cancer cells might inadvertently impact FMRP's function in neurons, leading to issues with synaptic plasticity and neural health. The gene discussed is FMR1; the disease is cancer.